BOSTON, Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, President and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. ET.A live w ...

财务表现 - 公司2022年第三季度营收为XX亿美元，同比增长XX%。[1] - 公司2022年前三季度营收为XX亿美元，同比增长XX%。[2] - 公司2022年第三季度净利润为XX亿美元，同比增长XX%。[1] - 公司2022年前三季度净利润为XX亿美元，同比增长XX%。[2] 业务发展 - 公司在XX领域取得了重大突破，推出了新产品XX。[1] - 公司在XX市场的份额进一步提升，实现了XX%的增长。[2] - 公司加大了在XX领域的投入和研发力度，为未来发展奠定了基础。[3] 战略规划 - 公司制定了未来三年的发展战略，聚焦于XX和XX两大领域。[3] - 公司将继续推进全球化战略，加大在XX市场的投入和拓展。[2] - 公司计划在未来一年内完成XX项目的并购整合。[4] 风险因素 - 受宏观经济环境不确定性的影响，公司面临着XX方面的挑战。[1] - 公司在XX领域的竞争压力有所增加，需要采取有效措施应对。[3] - 原材料价格波动和供应链不稳定性可能会对公司业绩产生一定影响。[4]

-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile ---- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress 2024 (ESMO-IO 2024) ---- Expect to initiate dosing ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40523 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1771427 ...

Investors might want to bet on Elevation Oncology, Inc. (ELEV) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The ...

Overview of the Recent Transaction On September 30, 2024, Empery Asset Management, I.P (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (ELEV, Financial). This transaction, exceuted at a price of $0.5999 per share, represents a notable increase in the firm's stake in the biotechnology company. The trade has increased Empery Asset Management's total holdings in ELEV to a substantial 4.99% of the company, marking a strategic mo ...

xphotoz/iStock via Getty Images Introduction The 'Undercovered' Dozen series highlights undercovered stocks on our platform for you to have another source for idea generation. This time we're looking at ideas published between August 1st - 8th. Take a look at what these less-covered ideas might hold for you. And please join the conversation below to share what you think: are any of these worth following up on? Ticker Rating Analyst OTCPK:SFTBY, OTCPK:SFTBF Hold Wide Alpha It does not matter how many Nobel P ...

The stock of Elevation Oncology Inc. ELEV is trading lower on Tuesday after the company reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, or esophageal cancers. As of the data cutoff date of June 10, 32 patients had been treated. EO-3021 was observed to be generally welltolerated. No Grade 4 or 5 treatment-r ...

肿瘤疗法研发 - 公司正在开发针对Claudin 18.2和HER3的两个靶点的创新型肿瘤疗法[150] - 公司的主要产品候选药EO-3021是一种针对Claudin 18.2的抗体偶联药物(ADC)，正在进行I期临床试验[151] - EO-3021在2020年11月和2021年5月分别获得FDA授予的治疗胃癌(包括胃食管交界癌)和胰腺癌的孤儿药资格[151] - 在Claudin 18.2表达≥20%的胃癌和胃食管交界癌患者中,EO-3021的客观缓解率为42.8%,疾病控制率为71.4%[157] - 公司计划在I期临床试验的扩展队列中进一步评估2.0 mg/kg和2.5 mg/kg剂量,并引入生物标志物筛选策略[159][160] - 公司暂停了抗HER3单抗seribantumab的进一步临床开发,将寻求与合作伙伴共同推进[162][163] 财务状况 - 公司研发和行政费用总计1.06亿美元，其中研发费用6,551万美元[190]，行政费用4,412万美元[194] - 公司在2024年上半年通过ATM融资方式共获得4,420万美元净融资[212] - 公司在2024年6月30日拥有1.108亿美元的现金、现金等价物和可流动性证券[214] - 公司在2024年上半年经营活动净现金流出1,778万美元[215] - 公司在2024年上半年投资活动净现金流出1,696万美元[215] - 公司在2024年上半年筹资活动净现金流入4,493万美元[215] - 公司预计未来资本支出将大幅增加,主要用于EO-3021的临床前和临床试验以及其他潜在产品的开发[222] - 公司预计截至2024年6月30日的现金、现金等价物和有价证券1.108亿美元将支持公司运营到2026年[224] - 公司可能需要通过公开或私募股权或债务融资等方式筹集额外资金,如果无法按有利条件筹集资金,可能会被迫延迟、减少或终止研发项目、商业化计划或其他运营[227] 合作与许可 - 公司与CSPC Pharmaceutical Group Limited签订了EO-3021在大中华区以外的开发和商业化许可协议[152] 临床试验结果 - EO-3021在I期临床试验中表现出良好的耐受性，未观察到已知的MMAE相关毒性[155][156]

临床试验结果 - Elevation Oncology宣布EO-3021在Claudin 18.2表达高的胃癌和胃食管交界癌患者中观察到42.8%的客观缓解率[2] - EO-3021在安全性方面表现良好,未观察到已知的毒性副作用[8] 未来计划 - 公司计划在2024年底前启动EO-3021联合疗法的临床试验[10] - 公司预计在2025年上半年公布EO-3021单药疗法的更多临床数据[11] - 公司计划在2024年下半年提名HER3-ADC项目的候选药物[12] 财务状况 - 公司2024年第二季度的现金、现金等价物和可流通证券总额为1.108亿美元,预计可为公司运营提供资金支持至2026年[13,17] - 2024年第二季度研发费用为655.1万美元,较2023年同期增加[14] - 2024年第二季度管理费用为441.2万美元,较2023年同期有所增加[15] - 2024年第二季度净亏损为1,046.1万美元[16]